-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Background: Traditionally, sulfonylureas of hypoglycemic agents (SUs) have been second only to metformin in type 2 diabetes
According to FDA regulations, SUs are required to include a product label when approved for use in the United States, stating that the use of SUs is associated
Materials and methods: We performed indirect treatment comparisons to determine the risk ratio of glimepiride to placebo in terms of 3-point MACE, all-cause death, CV death, and non-CV death, which is based on CV safety
Results: The ITC results showed that glemepiride had non-inferior efficacy compared with placebo at 3 points of MACE (hazard ratio 1.
Table 1 Summary
Conclusion: This result clearly indicates that glimepiride has a low all-cause risk of cardiovascular-related death, and its cardiovascular safety aspect is reassuring
Another study found that tolbutamide and gliclazide selectively bind to pancreatic SUR1 and not to SUR on cardiomyocyte membranes and vascular smooth muscle cell membranes
References:
[1] Ghosh S, Mukhopadhyay P, Pandey P, et al.
Tang Lizhi, Tong Nanwei.
